Completely agree with this! So many biopsies are done without a clear plan on how the biological samples would help move things forward!

🔍 Does AI reduce #clinician workload?

@NEJM study on @NuanceDragon DAX Copilot, an AI-powered documentation tool, found minimal impact on EHR efficiency & financial metrics❗️

💡AI tools need to be developed in comjuction with 🩺🥼🧑‍⚕️ not in silos
#AIinMedicine #LLMs @oncoalert.bsky.social

🚨 Breakthrough therapy for ES-SCLC!

@FDA grants sacituzumab govitecan BTD for ES-SCLC progressing on platinum chemo, based on phase II TROPiCS-03 data:
🔹 ORR: 41.9%
🔹 Disease control: 83.7%
🔹 Clinical benefit: 48.8%

Next step: phase III trials. 🤞 this provides another option

#LCSM #SCLC

Absolutely stunning progress in #lcsm! 🫁
📈 Each month of 2024 has brought incredible advancements—remarkable strides in lung cancer treatment! 💉
✨ Here's another perspective on this impressive journey. Just Ah-mazing! @oncodaily.bsky.social @n8pennell.bsky.social @jackwestmd.bsky.social

Completely agree! From my experience with testing companies, there’s often clarity on next steps but hesitancy in designing trials that truly assess the ‘value’ of tests. We can’t keep adding data to similar studies without meaningful progress.

Phase I Results AMG 193, PRMT5 inhibitor targeting MTAP-deleted solid tumors: @AnnalsOncology

• 📊 ORR: 21.4% across 8 tumor types (incl. NSCLC, pancreatic & biliary)
• 🛡️ Safety: minimal myelosuppression; nausea & fatigue
• 🎯 MoA: Synthetic lethality in MTAP-deleted cells! @oncoalert.bsky.social

📢 Breaking news in #SCLC treatment!

Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).

This approval marks an important step forward for patients with limited-stage SCLC! 💪

Just an amazing episode! Kudos @drcamidge.bsky.social, so touching! Dr. Camidge puts it so beautifully “Patients are people who happen to be patients and not patients who happen to be people, if you see what I mean.”
Must listen 🎧

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoi

Interesting…second line lung cancer trial positive (with caveats), now first line pancreatic cancer. Need to see the paper but TTF is here to stay it seems. Positive Topline Results from Phase 3 PANOVA-3Trial of Tumor Treating Fields for Pancreatic Ca.
www.businesswire.com/news/home/20...

A strategic position statement in @Annals_Oncology on the main actions to boost #lungcancer research and innovation:

✅ Pragmatic trials
✅ Ensure inclusivity and diversity
✅ NGS in resectable #NSCLC
✅ Exploit resistance mech
✅Focus on novel Tox

bit.ly/4ga8LlC

#LCSM #some @iaslc.bsky.social

Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!

www.nature.com/articles/s41...

aacrjournals.org/cancerres/ar...
Study by Herzog and colleagues suggesting cell type–specific epigenetic changes shared by e-cigarette use, smoking, and cancer
#lcsm #lcam @theaacr.bsky.social @fda.gov @iaslc.bsky.social @younglungcancer.bsky.social @lungevity.bsky.social

Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors AbstractBackground. Immune checkpoint inhibitors (ICIs) are associated with severe immune-related adverse events (s-irAEs) that result in hospitalization,

Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE

@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...

Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Introduction: Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, despite advances in immune checkpoint inhibitors and targeted therapies. Antibody–drug c...

⭐️Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Nice work spearheaded by @adesaimd.bsky.social

mdpi.com/3031120

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer AbstractPurpose:. Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted antibody conjugated to calicheamicin, was evaluated i...

Ph I trial ABBV-011 (SEZ6-ADC) in SCLC @theaacr.bsky.social

- SEZ6: Seizure-Related Homolog Protein 6 (IHC+ in SCLC)
- 99pts, 67% 2+lines
- TRAEs fatigue 50% nausea 42%
- 1mg/kg dose ORR 25%
- mDOR 4.2m

One to watch in SCLC
@oncoalert.bsky.social #OncSky #LCSM

aacrjournals.org/clincancerre...

Thrilled to be starting “AI in Health Care: From Strategies to Implementation program” @harvardmed! 🧠💻 Embarking on this to deepen my understanding and applications of AI to revolutionize #medicine and #oncology!
Excited to apply these insights to patient care! 🌟 #AIInMedicine #StudentforLife

Thanks to our amazing patient who brought in delicious White Ribbon cupcakes for the thoracic clinic team to celebrate #LungCancerAwarenessMonth #COH

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for lung cancer treatment. This follows earlier trial failures in 2023, though ...

Unfortunately, this may mean continually reducing interest in TIGIT as a target!

endpts.com/roches-tigit...

🧬 “Real-world Dabrafenib-Trametinib (D-T) for BRAF V600E-mutated NSCLC”
The IFCT-2004 BLaDE study confirms:
• Significant efficacy in both pretreated & untreated patients
• 12-month OS: 67.4%
• Median PFS: 10.4 (2L+), 18.2 mths (1L)

🔑 Early BRAF V600E testing is critical for optimizing therapy. 🎯

Honored to be nominated for ASCO Board of Directors along with 12 other qualified candidates. Only one week remaining to vote and make your voice heard!

society.asco.org/about-asco/a...

Anyone can get lung cancer.

Brandy learned this in 2023. Her diagnosed also clarified what truly matters: time with her guys.

Let's advocate for more research, so more people like Brandy have all the time in the world. @oncogenecancer.bsky.social

#BecauseofResearch #LCSM

Impact of lung biomarker testing on out-of-pocket costs for metastatic non-small cell lung cancer - @ClinicalLung
◾️ Median OOP cost of $98 (IQR: $43.8-$306.5)
◾️Biomarker testing total OOP cost of all services in 6 mths of diagnosis: $3560.2 compared to $1979.6 for those who did not! bit.ly/4hUTqaa

#LCSM is Lung Cancer Social Media. Please tag your LC related posts. It’s very helpful.

So #oncosky peeps, how are you using your #SoMe time these days?
1. BlueSky Only
2. X and BlueSky
3. X, BlueSky and LinkedIn
4. X, BlueSky, LinkedIn and Instagram/TikTok/Others? (At this point you have my deep respect 🙏)

Also just realized, @bsky.app needs a poll function!!!!

Illustration of main ADCs in clinical development for oncogene-addicted #NSCLC. Nice data for both biomarker-agnostic ( anti-TROP2) and biomarker-driven ADCs for various targets and payloads. Drug-to-Ab ratio is depicted by the N of red pins on the Ab surface. @iaslc.bsky.social
#some #lungcancer

Flew from Shanghai to Seattle to Lake Tahoe yday to attend #MaTOS24 conference today, where Claudia Henschke kicks off on screening.

Great to catch up with so many colleagues, many of whom have been prolific on X but may be thinking about transitioning here. Will try to nudge them along.

Ready to start the #MaTOS24 conference at Lake Tahoe with Drs. Luis Raez and Marina Garassino!

#FDAOncology approves a biparatopic, Zanidatamab- targeting HER2 for #BTCs
Based on HERIZON-BTC-01!
➡️ORR: 41.3%, mDOR=14.9 mths
➡️ Approval for IHC 3+, where TDX-d also has agnostic approval
➡️18% Gr3 TRAEs, diarrhea
#Oncosky @oncoalert.bsky.social @viveksubbiah.bsky.social

Exciting times in #NSCLC with multiple immunotherapy approvals in early stage! 🎉

But navigating these options can be complex. Glad to partner with @OncLearnNetwork to create patient case-based education, bridging the gap between advancements and real-world application.
bit.ly/498ffPB

#OncoSky! Sounds great!